Cargando…
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane
Measurement of tumour and normal tissue perfusion in vivo in cancer patients will aid the clinical development of antiangiogenic and antivascular agents. We investigated the potential antiangiogenic effects of the drug razoxane by measuring the changes in parameters estimated from H(2)(15)O and C(15...
Autores principales: | Anderson, H, Yap, J T, Wells, P, Miller, M P, Propper, D, Price, P, Harris, A L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394254/ https://www.ncbi.nlm.nih.gov/pubmed/12865914 http://dx.doi.org/10.1038/sj.bjc.6601105 |
Ejemplares similares
-
Razoxane-induced polyploidy.
por: Taylor, I. W., et al.
Publicado: (1978) -
Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma
por: Yeung, Timothy P C, et al.
Publicado: (2014) -
Reduction of daunomycin toxicity by razoxane.
por: Wang, G., et al.
Publicado: (1981) -
Imaging tumour hypoxia with positron emission tomography
por: Fleming, I N, et al.
Publicado: (2015) -
The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
por: Albanese, R., et al.
Publicado: (1985)